骨质疏松症（osteoporosis，OP）是一种非常普遍的疾病，特征是单位体积骨量的下降，增加患者的骨折风险，极大地降低患者的生活质量，对社会产生巨大的经济负担。线粒体是真核细胞的能量核心，涉及众多关键的生物过程，其功能出现异常会导致细胞功能不正常，进而诱发各种疾病。近期的研究揭示，线粒体质量控制（mitochondrial quality control，MQC）的失衡，包括线粒体氧化应激、动力学、自噬和生物生成异常等，在骨质疏松症中具有重要的作用。综述MQC在OP治疗？中的研究进展，同时总结靶向MQC进行OP治疗的中药（包括单体化合物和复方），以期为OP治疗新策略提供参考和借鉴。

Osteoporosis (OP) is a very prevalent disease characterized by a decrease in bone mass per unit volume, which increases the risk of fracture in patients, dramatically reduces their quality of life, and imposes a huge economic burden on society. Mitochondria are the energetic core of eukaryotic cells and are involved in numerous critical biological processes, and abnormalities in their function can lead to abnormal cellular function, which in turn induces various diseases. Recent studies have revealed that imbalances in mitochondrial quality control (MQC), including abnormalities in mitochondrial oxidative stress, kinetics, autophagy and biogenesis, have an important role in osteoporosis. This study reviews the research progress of MQC in OP, and summarizes the traditional Chinese medicines (including single compound and combinations) targeting MQC for OP treatment, with view to providing reference and reference for researching new strategies for OP treatment.

甘肃省自然科学基金项目（23JRRA1245）；兰州市人才创新创业项目（2020-RC-54）